Hematology · PANCE / PANRE

Monoclonal Gammopathy of Undetermined Significance (MGUS)

Written & clinically reviewed by Ryan Busch, PA-C · Updated October 2026 · Report an error

Asymptomatic premalignant plasma cell disorder with monoclonal protein <3 g/dL, marrow plasma cells <10%, no end-organ damage.

Also known as: MGUS, monoclonal gammopathy, benign monoclonal gammopathy

Overview

Asymptomatic premalignant clonal plasma cell disorder defined by the presence of a serum monoclonal protein (M-protein) <3 g/dL, clonal bone marrow plasma cells <10%, and absence of myeloma-defining events or end-organ damage attributable to a plasma cell disorder.

Epidemiology

Prevalence ~3% in adults >50 years, ~5% >70, ~7-8% >85. Higher prevalence in Black individuals (2-3 fold) and in men. Annual progression risk to multiple myeloma or related malignancy ~1% per year (cumulative — risk does not decrease over time).

Try two board-style Monoclonal Gammopathy of Undetermined Significance questions

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1HematologyMedium
A 68-year-old man is referred after routine bloodwork for fatigue showed an elevated total serum protein. He has no bone pain, weight loss, or recurrent infections. Examination is unremarkable, and CBC, serum calcium, and creatinine are normal. Serum protein electrophoresis with immunofixation reveals an IgG kappa monoclonal protein of 1.1 g/dL, and quantitative immunoglobulins show no suppression of the uninvolved isotypes. To complete the initial risk stratification of his monoclonal gammopathy, which of the following is the most appropriate next test?
  • AWhole-body skeletal survey x-rays
  • BCongo red stain of fat pad aspirate
  • CSerum free light chain ratio assay
  • DBone marrow aspiration and biopsy
  • ESerum beta-2 microglobulin level
Reveal answer & full explanation
Correct answer: C — Serum free light chain ratio assay
  • AWhole-body skeletal survey x-rays
  • BCongo red stain of fat pad aspirate
  • CSerum free light chain ratio assay✓
  • DBone marrow aspiration and biopsy
  • ESerum beta-2 microglobulin level

Why Serum free light chain ratio assay is correct

  • The IMWG/Mayo workup of a newly detected monoclonal gammopathy pairs SPEP with immunofixation and a serum free light chain assay; the kappa/lambda ratio is one of the three Mayo risk-stratification factors (M-protein >=1.5 g/dL, non-IgG isotype, abnormal FLC ratio).
  • This patient has a low-burden IgG kappa M-protein (<3 g/dL) with normal CBC, calcium, and creatinine and no immunoparesis, consistent with MGUS; an abnormal FLC ratio would raise his progression risk and intensify surveillance, so it is the appropriate next step before any invasive or imaging study.

Why the others are wrong

  • Bone marrow aspiration and biopsy is reserved for higher-risk features (M-protein >=1.5 g/dL, non-IgG isotype, abnormal FLC ratio, or unexplained cytopenias); ordering it before the FLC result in a low-burden IgG case is premature and out of sequence.
  • Whole-body skeletal survey x-rays are outdated; plain-film surveys have been replaced by whole-body low-dose CT, MRI, or PET-CT, and advanced imaging is reserved for intermediate/high-risk, IgA, or light-chain disease, not routine low-risk stratification.
  • Congo red stain of fat pad aspirate tests for AL amyloidosis, which is suggested by cardiac, renal, or neuropathic involvement; this asymptomatic patient with normal organ function has no features prompting an amyloid biopsy.
  • Serum beta-2 microglobulin level — beta-2 microglobulin stages established multiple myeloma (with albumin in the ISS), which makes it tempting in a gammopathy workup, but it is not one of the three Mayo MGUS risk factors and plays no role in stratifying this low-burden IgG MGUS.
Question 2HematologyMedium
A 68-year-old man is referred after routine labs for fatigue showed an elevated total protein. Serum protein electrophoresis reveals an IgG kappa M-protein of 1.1 g/dL. Hemoglobin, calcium, and creatinine are normal, and a serum free light chain ratio is only mildly abnormal. Bone marrow biopsy shows 4% clonal plasma cells, and whole-body low-dose CT shows no lytic lesions. He is diagnosed with monoclonal gammopathy of undetermined significance and enrolled in lifelong surveillance. Which of the following complications is he most likely to develop over time?
  • ASymptomatic multiple myeloma
  • BLight-chain (AL) amyloidosis
  • CWaldenström macroglobulinemia
  • DChronic lymphocytic leukemia
  • EMarginal zone B-cell lymphoma
Reveal answer & full explanation
Correct answer: A — Symptomatic multiple myeloma
  • ASymptomatic multiple myeloma✓
  • BLight-chain (AL) amyloidosis
  • CWaldenström macroglobulinemia
  • DChronic lymphocytic leukemia
  • EMarginal zone B-cell lymphoma

Why Symptomatic multiple myeloma is correct

  • MGUS is a premalignant clonal plasma cell disorder; its highest-yield complication is progression to multiple myeloma at a rate of roughly 1% per year, and this cumulative risk does NOT decline over time, which is why lifelong surveillance is appropriate.
  • This patient has the non-IgM (IgG) subtype, which carries risk of progression to multiple myeloma (or, less commonly, AL amyloidosis or a B-cell lymphoma) rather than to a lymphoplasmacytic disorder.
  • Per IMWG criteria he meets MGUS (M-protein <3 g/dL, clonal marrow plasma cells <10%, no CRAB), and the Mayo risk model (M-protein >=1.5 g/dL, non-IgG isotype, abnormal FLC ratio) stratifies that ~1%/year progression risk.

Why the others are wrong

  • Waldenström macroglobulinemia — the lymphoplasmacytic malignancy that an IgM MGUS clone progresses toward; this patient has an IgG (non-IgM) M-protein, so myeloma, not Waldenström, is the expected endpoint.
  • Chronic lymphocytic leukemia — a clonal B-lymphocyte (not plasma cell) malignancy with smudge cells and CD5/CD23 expression; it is not the malignancy MGUS evolves into.
  • Marginal zone B-cell lymphoma — a B-cell lymphoma associated with chronic immune stimulation; while non-IgM MGUS carries a small risk of a B-cell lymphoma, progression to multiple myeloma is far more common and is the single most likely endpoint here.
  • Light-chain (AL) amyloidosis — a clonal plasma cell population with an abnormal free light chain ratio can deposit light chains as amyloid fibrils, and non-IgM MGUS does carry this risk, but AL amyloidosis is much less common than progression to multiple myeloma, which remains the most likely endpoint.

That's 2. Get 7,700+ more.

Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial →
🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Monoclonal Gammopathy of Undetermined Significance (MGUS) outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → Sign in
Free to start · No credit card · Cancel anytime

Risk factors

  • Advancing age
  • Black race / African ancestry
  • Male sex
  • Family history of MGUS or multiple myeloma
  • Exposure to pesticides, herbicides, ionizing radiation
  • Chronic immune stimulation — autoimmune disease, HIV, HCV

Pathophysiology

Clonal plasma cells in the bone marrow produce a homogeneous immunoglobulin (M-protein). Unlike multiple myeloma, the clone has not acquired the additional genetic hits required to produce overt malignancy with end-organ injury. Cytogenetic abnormalities (IgH translocations involving 11q13, 4p16, 16q23; trisomies; del 17p) are similar to MM, suggesting MGUS is a true precursor.

Clinical presentation

Symptoms

  • Asymptomatic — typically discovered incidentally on workup for elevated total protein, neuropathy, or unrelated illness
  • Rarely associated symptoms: peripheral neuropathy (especially IgM MGUS with anti-MAG antibodies)

Signs / physical exam

  • No specific findings
  • No anemia, lytic lesions, renal dysfunction, or hypercalcemia attributable to MGUS
  • Possible findings of underlying associated condition (e.g., neuropathy in IgM MGUS)

Classic findings

Incidental M-spike on serum protein electrophoresis (SPEP) in an asymptomatic older adult.

Differential diagnosis

  • Multiple myeloma — Clonal marrow plasma cells ≥10% (or biopsy-proven plasmacytoma) with any M-protein level, AND end-organ damage (CRAB) or biomarkers (≥60% plasma cells, FLC ratio ≥100, MRI focal lesions ≥2)
  • Smoldering multiple myeloma — M-protein ≥3 g/dL OR marrow plasma cells 10-60% WITHOUT CRAB or biomarkers
  • Waldenström macroglobulinemia — IgM M-protein + lymphoplasmacytic infiltrate; MYD88 L265P mutation
  • Light chain amyloidosis (AL) — Cardiac, renal, neuropathic involvement; Congo red-positive amyloid on biopsy; abnormal FLC ratio
  • POEMS syndrome — Polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes; elevated VEGF
  • Solitary plasmacytoma — Single bone or extramedullary lesion; marrow uninvolved

Diagnostic workup

Diagnostic criteria

IMWG criteria — ALL three required: 1) Serum M-protein <3 g/dL 2) Clonal bone marrow plasma cells <10% 3) Absence of myeloma-defining events: hypercalcemia, renal dysfunction, anemia, bone lesions (CRAB); plus absence of amyloidosis or other plasma cell disorder. Subtypes: non-IgM MGUS (IgG, IgA), IgM MGUS, and light chain MGUS.

Labs

  • Serum protein electrophoresis (SPEP) with immunofixation (IFE) — identify and quantify M-protein
  • Serum free light chain (FLC) assay with kappa/lambda ratio — abnormal ratio is a risk factor for progression
  • Quantitative immunoglobulins (IgG, IgA, IgM) — assess for immunoparesis (suppression of uninvolved Igs)
  • CBC, BMP, calcium, albumin, LDH, beta-2 microglobulin — assess for CRAB criteria
  • Urine protein electrophoresis (UPEP) with immunofixation, 24-h urine — assess for light chain (Bence Jones) proteinuria
  • Bone marrow biopsy if M-protein ≥1.5 g/dL, non-IgG isotype, abnormal FLC ratio, or unexplained cytopenias/symptoms

Imaging

  • Whole-body low-dose CT, MRI, or PET-CT to evaluate for lytic lesions if intermediate/high-risk MGUS, IgA or light chain isotype, or symptomatic — replaces traditional skeletal survey
  • Cardiac MRI / echocardiogram if amyloidosis suspected (NT-proBNP, troponin, FLC ratio)

Treatment

First-line

  • NO TREATMENT — observation only
  • Risk-stratified surveillance based on Mayo Clinic risk model (non-IgG isotype, M-protein ≥1.5 g/dL, abnormal FLC ratio)
  • 0 risk factors (low risk) — repeat SPEP in 6 months, then every 2-3 years if stable
  • 1-3 risk factors (intermediate to high risk) — annual SPEP indefinitely; consider baseline bone marrow biopsy and imaging

Low-risk MGUS

  • SPEP/FLC at 6 months, then every 2-3 years if stable
  • Bone marrow biopsy not initially required
  • Patient education re symptoms warranting earlier evaluation

Intermediate/high-risk MGUS

  • Baseline bone marrow biopsy and whole-body imaging
  • Annual SPEP, FLC, CBC, calcium, creatinine indefinitely
  • Bisphosphonate (alendronate, zoledronic acid) for osteopenia/osteoporosis — increased fracture risk in MGUS

IgM MGUS

  • Annual surveillance
  • Evaluate for Waldenström macroglobulinemia and IgM-related disorders (anti-MAG neuropathy, cryoglobulinemia, cold agglutinin disease)

Second-line / adjunct

  • Refer to hematology if M-protein rises, FLC ratio worsens, cytopenias develop, or CRAB features emerge
  • Treat associated conditions (e.g., rituximab for symptomatic IgM-related neuropathy or cryoglobulinemia)

Complications

  • Progression to multiple myeloma (~1% per year, lifelong)
  • Progression to Waldenström macroglobulinemia (IgM subtype), AL amyloidosis, or B-cell lymphoma
  • Increased risk of osteoporosis and fragility fractures
  • Increased risk of venous thromboembolism (modest)
  • Renal disease — monoclonal gammopathy of renal significance (MGRS) requires hematology evaluation despite low M-protein

PANCE pearls

  • MGUS is NEVER treated with chemotherapy — only observed.
  • Cumulative risk of progression is ~1% per year and does NOT decline over time — lifelong surveillance is appropriate.
  • Mayo risk model uses three factors: M-protein ≥1.5 g/dL, non-IgG isotype, abnormal FLC ratio (0-3 risk factors).
  • Skeletal surveys (plain films) have been replaced by whole-body low-dose CT, MRI, or PET-CT for higher-resolution lesion detection.
  • Even with normal M-protein, kidney biopsy may reveal monoclonal gammopathy of renal significance (MGRS) — refer to hematology.
  • IgM MGUS carries risk of Waldenström, not multiple myeloma; the surveillance focus is different.

References

  • IMWG — Rajkumar SV et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15:e538-548.
  • Mayo Clinic risk model — Rajkumar SV et al. Serum free light chain ratio is an independent risk factor for progression in MGUS. Blood 2005; 106:812-817.
  • IMWG MGUS monitoring consensus — Kyle RA et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24:1121-1127.

Practice Hematology questions on FirstPassPA

Turn this outline into retention. 7,700+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Start your 7-day free trial → Get today's free question →

Studying for an EOR?

Free Family Medicine EOR questions →Free Emergency Medicine EOR questions →Family Medicine EOR study guideEmergency Medicine EOR study guide

Commonly confused with

vs Multiple Myeloma

Related Hematology diagnoses

Iron Deficiency AnemiaAnemia of Chronic Disease (Anemia of Inflammation)Vitamin B12 Deficiency / Pernicious AnemiaFolate Deficiency AnemiaSickle Cell DiseaseThalassemia (Alpha and Beta)G6PD DeficiencyAplastic AnemiaWarm Autoimmune Hemolytic AnemiaImmune Thrombocytopenic Purpura (ITP)Thrombotic Thrombocytopenic Purpura (TTP) / Hemolytic Uremic Syndrome (HUS)Disseminated Intravascular Coagulation (DIC)Hemophilia A and BVon Willebrand Disease

Differentials & related conditions

Multiple Myeloma

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.